熱門資訊> 正文
宣布对主要资产进行后期试验，Corvus激增
2024-09-11 02:43
- Shares of Corvus Pharmaceuticals (NASDAQ:CRVS) gained on Tuesday after the company announced the beginning of a Phase 3 registrational trial for its lead candidate, soquelitinib, in peripheral T-cell lymphoma (PTCL).
- The California-based biotech added that the global trial is expected to enroll about 150 patients with relapsed/refractory PTCL at approximately 40 sites in countries including the U.S. and Canada.
- "The initiation of the soquelitinib Phase 3 trial for relapsed PTCL is an important milestone for Corvus and for patients suffering with this disease," CEO Richard Miller added.
- The trial designed to evaluate soquelitinib as a late-line option will assess progression-free survival as its primary goal, while overall survival, objective response rate, and duration of response will be among some of its secondary goals.
More on Corvus Pharmaceuticals
- Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL
- Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
- Corvus Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation
- Corvus Pharmaceuticals GAAP EPS of -$0.07 beats by $0.05
- Seeking Alpha’s Quant Rating on Corvus Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
